Escitalopram versus placebo in the treatment of dysthymic disorder

International Clinical Psychopharmacology

Volumn 25, Issue 3, 2010, Pages 143-148

  Hellerstein, David J ^c   Batchelder, Sarai T ^b   Hyler, Steven ^a   Arnaout, Bachaar ^b   Toba, Christina ^a   Benga, Ileana ^a   Gangure, Dinu ^b  

^a St Luke's Roosevelt Hospital Center   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Surgeons New York DYale University ^*  (United States)

Author keywords

Depression; Dysthymic disorder; Escitalopram; Psychopharmacology

Indexed keywords

ESCITALOPRAM; PLACEBO;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSTHYMIA; EJACULATION DISORDER; FEMALE; HAMILTON SCALE; HUMAN; MALE; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL ADAPTATION; SOCIAL INTERACTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSTHYMIC DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; STEREOISOMERISM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950949931     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328333c35e     Document Type: Article

References (23)

1. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK (1961). An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
2. Friedman RA (1993). Social impairment in dysthymia. Psych Annals 23:632-637.
3. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K (1995). Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 52:11-19.
4. Hellerstein DJ (2001). Dysthymic disorder: integrating research findings into clinical treatment. J Psychiatr Pract 7:298-309.
5. Hellerstein DJ, Batchelder S, Lee A, Borisovaskaya M (2002). Rating dysthymia: an assessment of the construct and content validity of the Cornell Dysthymia Rating Scale. J Affect Disord 71:85-96.
6. Hellerstein DJ, Batchelder S, Miozzo R, Kreditor D, Hyler S, Gangure D, Clark J (2004). Citalopram in the treatment of dysthymic disorder. Int Clin Psychopharmacol 19:143-148.
7. Keller MB (1994). Dysthymia in clinical practice: course, outcome and impact on the community. Acta Psychiatrica Scandinavica 383 (Suppl):24-34.
8. Kessler RC, Chiu WT, Demler O, Walters EE (2005). Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 62:617-627. (Pubitemid 40973437)
9. Klein DN, Schwartz JE, Rose S, Leader JB, (2000). Five-year course and outcome of dysthymic disorder: a prospective, naturalistic follow-up study. Am J Psychiatry 157:931-939.
10. Klein DN, Shankman SA, Rose S (2006). Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry 163:872-880.
11. Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, et al. (1997). Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 154:390-395.
12. Lima MS and Moncrieff J (2007). Drugs versus placebo for dysthymia. The Cochrane Database of Systematic Reviews.
13. Markowitz JC (1998). Interpersonal psychotherapy in dysthymic disorder. Washington DC: American Psychiatric Press.
14. Mason BJ, Kocsis JH, Leon AC, Thomson S, Frances AJ, Morgan RO, Parides MK (1993). Measurement of severity and treatment response in dysthymia. Psychiatric Annals 23:625-631.
15. McCullough JP (2003). Treatment for chronic depression: cognitive behavioral analysis system of psychotherapy (CBASP). New York: Guilford.
16. Moore N, Verdoux H, Fantino B (2005). Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20:131-137.
17. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905-1917.
18. Rush AJ (2007). STAR*D: what have we learned? Am J Psychiatry 164: 201-204.
19. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, et al. (1996). A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 53: 777-784.
20. Veale D (2008). Behavioural activation for depression. Adv Psychiatric Treatment 14:29-36.
21. Weissman MM, Bothwell S (1976). Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 33:1111-1115.
22. Weissman MM, Prusoff BA, Thompson WD, Harding ES, Myers JK (1978). Social adjustment by self-report in a community sample and in psychiatric outpatients. J Nervous Mental Dis 166:317-326.
23. Weissman MM, Leaf PJ, Bruce ML, Florio L (1988). The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment. Am J Psychiatry 145:815-819.